Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL von Kantarjian, Hagop, Giles, Francis, Wunderle, Lydia, Bhalla, Kapil, O'Brien, Susan, Wassmann, Barbara, Tanaka, Chiaki, Manley, Paul, Rae, Patricia, Mietlowski, William, Bochinski, Kathy, Hochhaus, Andreas, Griffin, James D, Hoelzer, Dieter, Albitar, Maher, Dugan, Margaret, Cortes, Jorge, Alland, Leila, Ottmann, Oliver G

Volltext

Safety of AFM11 in the treatment of patients with B-cell malignancies: findings from two phase 1 studies von Topp, Max, Dlugosz-Danecka, Monika, Skotnicki, Aleksander B, Salogub, Galina, Viardot, Andreas, Klein, Andreas K, Hess, Georg, Michel, Christian S, Grosicki, Sebastian, Gural, Alex, Schwarz, Sylvia E, Pietzko, Kerstin, Gärtner, Ulrike, Strassz, András, Alland, Leila, Mayer, Jiri

Volltext

AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has In vitro Activity against Imatinib-Resistant Chronic Myeloid Leukemia von GOLEMOVIC, Mirna, VERSTOVSEK, Srdan, ARLINGHAUS, Ralph B, TONG SUN, KANTARJIAN, Hagop, BERAN, Miloslav, GILES, Francis, CORTES, Jorge, MANSHOURI, Taghi, MANLEY, Paul W, MESTAN, Jürgen, DUGAN, Margaret, ALLAND, Leila, GRIFFIN, James D

Volltext

Randomized Phase III Trial of Pegylated Liposomal Doxorubicin Versus Vinorelbine or Mitomycin C Plus Vinblastine in Women With Taxane-Refractory Advanced Breast Cancer von KELLER, Alan M, MENNEL, Robert G, MELLARS, Lillian, ALLAND, Leila, TENDLER, Craig, GEORGOULIAS, Vassilis A, NABHOLTZ, Jean-Marc, ERAZO, Aura, LLUCH, Anna, VOGEL, Charles L, KAUFMANN, Manfred, VON MINCKWITZ, Gunther, HENDERSON, I. Craig

Volltext

Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein von DAVID, G, ALLAND, L, HONG, S.-H, WONG, C.-W, DEPINHO, R. A, DEJEAN, A

Volltext

AMN107, a novel aminopyrimidine inhibitor of p190 Bcr‐Abl activation and of in vitro proliferation of Philadelphia‐positive acute lymphoblastic leukemia cells von Verstovsek, Srdan, Golemovic, Mirna, Kantarjian, Hagop, Manshouri, Tashi, Estrov, Zeev, Manley, Paul, Sun, Tong, Arlinghaus, Ralph B., Alland, Leila, Dugan, Margaret, Cortes, Jorge, Giles, Francis, Beran, Miloslav

Volltext

A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma von Bartlett, Nancy L., Herrera, Alex F., Domingo-Domenech, Eva, Mehta, Amitkumar, Forero-Torres, Andres, Garcia-Sanz, Ramon, Armand, Philippe, Devata, Sumana, Izquierdo, Antonia Rodriguez, Lossos, Izidore S., Reeder, Craig, Sher, Taimur, Chen, Robert, Schwarz, Sylvia E., Alland, Leila, Strassz, Andras, Prier, Kim, Choe-Juliak, Cassandra, Ansell, Stephen M.

Volltext

Identification of Mammalian Sds3 as an Integral Component of the Sin3/Histone Deacetylase Corepressor Complex von Alland, Leila, David, Gregory, Shen-Li, Hong, Potes, Jason, Muhle, Rebecca, Lee, Hye-Chun, Hou, Harry, Chen, Ken, DePinho, Ronald A.

Volltext

Phase I analysis from the PYNNACLE phase I/II study of PC14586 in the subgroup of patients with advanced ovarian cancer harboring a TP53 Y220C mutation von Schram, Alison, Shapiro, Geoffrey, Thompson, John, Vandross, Andrae, Kummar, Shivaani, El-Khoueiry, Anthony, LeDuke, Kim, Fellous, Marc, Alland, Leila, Dumbrava, Ecaterina

Volltext

Abstract 5806: Combination of the miniature drug conjugate PEN-866 with PARP inhibitors as a rational approach to overcoming limitations of PARP inhibitor monotherapy von Perino, Samantha, Quinn, James M., Callahan, Marrissa, Sharma, Gitanjali, White, Brian, Bilodeau, Mark, Alland, Leila, Whalen, Kerry, Wooster, Richard

Volltext

First-in-human study of PC14586, a small molecule structural corrector of Y220C mutant p53, in patients with advanced solid tumors harboring a TP53 Y220C mutation von Dumbrava, Ecaterina Elena, Johnson, Melissa Lynne, Tolcher, Anthony W., Shapiro, Geoffrey, Thompson, John A., El-Khoueiry, Anthony B., Vandross, Andrae Lavon, Kummar, Shivaani, Parikh, Aparna Raj, Munster, Pamela N., Daly, Erika, De Leon, Laura, Khaddar, Megan, LeDuke, Kimberley, Robell, Kimberly, Sheehan, Lisa Iacono, St. Louis, Meagen, Wiebesiek, Amy, Alland, Leila, Schram, Alison M.

Volltext

A Phase 1 Study Investigating AFM11 in Patients with Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia: Preliminary Results von Salogub, Galina, Mayer, Jiri, Folber, Frantisek, Grosicki, Sebastian, Skotnicki, Aleksander B, Prochwicz, Anna, Myasnikov, Alexander, Gural, Alexander, Schoenborn-Kellenberger, Oliver, Brindley, Charlie, Knackmuss, Stefan, Schwarz, Sylvia, Schmich, Sandra, Choe-Juliak, Cassandra, Strassz, Andras, Alland, Leila, Doubek, Michael

Volltext

First in human phase 1/2a study of PEN-221 somatostatin analog (SSA)-DM1 conjugate for patients (PTS) with advanced neuroendocrine tumor (NET) or small cell lung cancer (SCLC): Pha... von Johnson, Melissa Lynne, Meyer, Tim, Halperin, Daniel M., Fojo, Antonio Tito, Cook, Natalie, Blaszkowsky, Lawrence Scott, Schlechter, Benjamin L., Yao, James C., Jemiai, Yannis, Kriksciukaite, Kristina, Jones, Marsha, Ezema, Nneamaka, Mei, Laura, Alland, Leila, Kulke, Matthew H.

Volltext

A Phase 1b Study Investigating the Combination of the Tetravalent Bispecific NK Cell Engager AFM13 and Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Bre... von Bartlett, Nancy L., Chen, Robert W., Domingo-Domenech, Eva, Forero-Torres, Andres, Garcia-Sanz, Ramon, Armand, Philippe, Devata, Sumana, Rodriguez Izquierdo, Antonia, Lossos, Izidore S., Reeder, Craig B., Sher, Taimur, Choe-Juliak, Cassandra, Prier, Kim, Schwarz, Sylvia, Strassz, Andras, Alland, Leila, Ansell, Stephen M.

Volltext

Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression von Alland, Lelia, Muhle, Rebecca, Hou, Harry, Potes, Jason, Chin, Lynda, Schreiber-Agus, Nicole, DePinho, Ronald A

Volltext

Abstract LB_A25: Updated Phase 1 results from the PYNNACLE Phase 1/2 study of PC14586, a selective p53 reactivator, in patients with advanced solid tumors harboring a  TP53   Y220C... von Schram, Alison M, Shapiro, Geoffrey I, Johnson, Melissa L, Tolcher, Anthony W., Thompson, John A, El-Khoueiry, Anthony B, Vandross, Andrae L, Kummar, Shivaani, Parikh, Aparna R, Shepard, Dale R, Garczarek, Ursula, LeDuke, Kim, Sheehan, Lisa, Fellous, Marc, Alland, Leila, Dumbrava, Ecaterina E

Volltext

Phase I Dose-Escalation Study of the Novel Antiandrogen BMS-641988 in Patients with Castration-Resistant Prostate Cancer von RATHKOPF, Dana, LIU, Glenn, FUNG, Nga Kit Eliza, CHENG, Shinta, JINPING GAN, GOTTARDIS, Marco, OBERMEIER, Mary T, REDDY, Jyotsna, ZHANG, Steven, VAKKALAGADDA, Blisse J, ALLAND, Leila, WILDING, George, CARDUCCI, Michael A, SCHER, Howard I, EISENBERGER, Mario A, ANAND, Aseem, MORRIS, Michael J, SLOVIN, Susan F, SASAKI, Yasutsuna, TAKAHASHI, Shunji, OZONO, Seiichiro

Volltext

Abstract B109: AZD5363, a catalytic pan-Akt inhibitor, in Akt1 E17K mutation positive advanced solid tumors von Hyman, David M., Smyth, Lillian, Bedard, Philippe L., Oza, Amit, Dean, Emma, Armstrong, Anne, Lima, Joao, Bando, Hideaki, Kabos, Peter, Perez-Fidalgo, J. Alejandro, Moore, Kathleen, Westin, Shannon N., You, Benoit, Chandarlapaty, Sarat, Alland, Leila, Ambrose, Helen, Foxley, Andrew, Lindemann, Justin, Pass, Martin, Rugman, Paul, Salim, Shaista, Schiavon, Gaia, Tamura, Kenji, Baselga, Jose, Banerji, Udai

Volltext

BMS-911543, A Selective JAK2 Inhibitor: A Multicenter Phase 1/2a Study In Myelofibrosis von Pardanani, Animesh, Roberts, Andrew W., Seymour, John F., Burbury, Kate, Verstovsek, Srdan, Kantarjian, Hagop M., Begna, Kebede, Yoshitsugu, Hiroyuki, Gestone, Toni Ann, Phillips, Penny, Xing, Guan, Peltz, Gerson, Lorenzi, Matthew V, Alland, Leila, Woolfson, Adrian, Tefferi, Ayalew

Volltext

Phase 0 clinical trials: Recommendations from the task force on methodology for the development of innovative cancer therapies von Kummar, Shivaani, Doroshow, James H, Tomaszewski, Joseph E, Calvert, A. Hilary, Lobbezoo, Marinus, Giaccone, Giuseppe

Volltext